Compare SKYX & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYX | CRBU |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.3M | 166.6M |
| IPO Year | 2014 | 2021 |
| Metric | SKYX | CRBU |
|---|---|---|
| Price | $1.18 | $1.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.00 | ★ $10.75 |
| AVG Volume (30 Days) | 1.9M | ★ 2.6M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.11 | 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,700,948.00 | N/A |
| Revenue This Year | $25.12 | $1.63 |
| Revenue Next Year | $24.18 | $10.93 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.78 | N/A |
| 52 Week Low | $0.95 | $1.38 |
| 52 Week High | $3.29 | $3.53 |
| Indicator | SKYX | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 39.45 |
| Support Level | $1.00 | $1.39 |
| Resistance Level | $1.29 | $1.73 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 65.16 | 21.82 |
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.